A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)
Merck Sharp & Dohme LLC
770 participants
Apr 9, 2025
INTERVENTIONAL
Conditions
Summary
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
IV Infusion
IV Infusion
Rescue medication taken per approved product label before sacituzumab tirumotecan
Rescue medication taken per approved product label before sacituzumab tirumotecan
Rescue medication taken per approved product label before sacituzumab tirumotecan
Rescue medication taken per approved product label before sacituzumab tirumotecan
Rescue medication taken orally 2-4 times daily
Locations(164)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06824467